ClinicalTrials.gg
RecruitingNCT06057181HRNUpdated Nov 12, 2026

Helix Research Network

An observational study in Genetic Predisposition to Disease and Genetics Disease, sponsored by Helix, Inc. Recruiting at 14 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Helix, Inc · Observational

How we know

From the registry’s dates

  • Started Sep 2021; still recruiting 5 years 2 months later.
Updated Nov 12, 2026Enrollment updatedInterventions changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Ecologic or community
Time perspective
Other
Enrollment
10,000,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 87 studies in Genetic Predisposition to Disease with a site in United States — 37 open to participants now, 46 under way, none of them phase 3. Genetic Predisposition to Disease · United States.

Planned enrollment
Largest of 50
10,000,000 · median 560
Started
2021
with 9 others
Observational
50 of 87
23 open now
Primary completion
2031-09
later than 41 of 45 live
Registered
67th of 87
by date

Among the 87 studies in Genetic Predisposition to Disease with a site in United States, this one has the largest planned enrollment of the 50 observational ones that give a count, is one of 10 that started in 2021, is one of 50 observational ones, reaches primary completion later than 41 of the 45 other live ones, and was the 67th registered.

Genetic Predisposition to Disease

242 studies on the registry are indexed under Genetic Predisposition to Disease; 96 are open to participants now.

Browse Genetic Predisposition to Disease studies →

Open to participants now

37 of the 87 studies in Genetic Predisposition to Disease with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 71 Genetic Predisposition to Disease studies recruiting now, 36 (51%) set no upper age limit and 28 (39%) stop at 75 or younger; 25 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Genetic Predisposition to Disease with a site in United States, or all of them as a file.
02

Study summary

The Helix Research Network ("HRN") is a network of academic, public, and/or private healthcare organizations that are committed to advancing medical research and improving human health through large-scale genomics research and acceleration of the integration of genomic and other multi-omics data into clinical care.

Read the detailed description

The network will create a large-scale clinicogenomics dataset, which will support research to discover molecular and genetic determinants of disease risk, disease progression, treatment response, health economic outcomes, social or behavioral determinants of health, targets for therapeutic intervention, risk stratification, clinical implementation, and other clinical indicators of interest. This clinicogenomics dataset will be used to reveal molecular and/or genetic factors that could improve the diagnosis or medical treatment of individual participants and includes a process to share individual results with participants. Participants will also receive annual reports on study outcomes and the impact of HRN, as such information becomes available.

Institutional membership in HRN will consist of Helix and member healthcare systems (herein referred to as "HRN Member Site(s)"). The Helix Research Network is a multi-center research program that will enroll an unlimited number of participants. Participants will be recruited concurrently from HRN Member Sites. In some cases, HRN Member Sites may recruit participants from multiple clinical sites. Participants who meet the enrollment criteria established in this protocol will be enrolled if they or their legally authorized representative(s) provide informed consent in accordance with all applicable regulations and sIRB requirements. Participants will be enrolled until withdrawal from the study or end of the study. Participants may be recruited at any point during the study period, until the recruitment goals established by the protocol are met.

03

Conditions studied

  • Genetic Predisposition to Disease
  • Genetics Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study will recruit the general population from the surrounding areas of the HRN Member Sites. This may include patients within a health system of the Site or community members in the surrounding area of Sites.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years and older
  • Willing and able to comply with all aspects of the protocol

Exclusion criteria

Exclusion Criteria:

  • History of allogenic bone marrow transplant
  • History of allogenic stem cell transplant
  • Anything that would place the individual at increased risk or preclude an individual's: 1) full compliance with study requirements; or 2) completion of the study based on the assessment from local consenting and enrolling Investigators.
05

Study design

Observational model
Ecologic or community
Time perspective
Other
Enrollment
10,000,000 participants (estimated)
Patient registry
No

Interventions

  • GeneticExome+ sequencing and multi-omics

    Exome sequencing will be completed on each sample submitted.

06

What researchers measure

Primary outcomes

  1. Establish a Research Network

    Establish a research network to support the advancement of biomedical research, improve human health through genomics research, and accelerate integration of genomic and other omics data into clinical care.

    Time frame: Through study completion, average 10 years

  2. Aggregate data

    Aggregate molecular, genomic data, phenotypic and other health-related data in centralized and/or federated databases to be accessed by investigators for approved research purposes.

    Time frame: Through study completion, average 10 years

  3. Re-Contact participants

    Recontact participants for additional data collection, research participation opportunities, and return of results

    Time frame: Through study completion, average 10 years

  4. Genetic biomarker identification

    Identification and characterization of clinical, histological, molecular, and genetic biomarkers that are linked to disease, disease outcomes, or that might be used to improvise disease classification.

    Time frame: Through study completion, average 10 years

  5. Exploration of genetic determinants of disease

    Exploration of the molecular and genetic underpinnings and determinants of disease, including disease risk, disease progression, treatment response, health economic outcomes, social or behavioral determinants of health, targets for therapeutic intervention, risk stratification, and other clinical indicators of interest.

    Time frame: Through study completion, average 10 years

  6. Collection and analysis of Patient Reported Outcomes

    Collection and analysis of Patient Reported Outcomes (e.g. quality of life, physical function, symptom burden) associated with diseases that have a genetic or molecular etiology. Validation of disease-specific instruments to assess the impact of genetic screening.

    Time frame: Through study completion, average 10 years

07

Study locations

14 of 14 sites recruiting
  • Parkview Health (DNA Insights)
    Fort Wayne, Indiana 46845, United States
    Recruiting
  • HealthPartners (myGenetics)
    Bloomington, Minnesota 55425, United States
    Recruiting
  • Nebraska Medicine - University of Nebraska Medical Center (Genetic Insights Project)
    Omaha, Nebraska 68198, United States
    Recruiting
  • Renown Health (Healthy Nevada Project)
    Reno, Nevada 89502, United States
    Recruiting
  • Rochester Regional Health (GenoWell)
    Rochester, New York 14621, United States
    Recruiting
  • Cone Health (Gene Connect)
    Burlington, North Carolina 27401, United States
    Recruiting
  • WakeMed (PreciselyYou)
    Raleigh, North Carolina 27610, United States
    Recruiting
  • TriHealth (DNA Discovery)
    Cincinnati, Ohio 45202, United States
    Recruiting
  • The Ohio State University (Genomic Health)
    Columbus, Ohio 43210, United States
    Recruiting
  • St. Luke's University Health Network (DNAanswers)
    Bethlehem, Pennsylvania 18015, United States
    Recruiting
    • Jean Reinert · ContactDNAanswers@sluhn.org · 484-658-6300
    • Christopher Chapman, MD · Principal investigator
  • WellSpan Health (The Gene Health Project)
    York, Pennsylvania 17403, United States
    Recruiting
    • Rebecca Eberly, BSN · Contactreberly2@wellspan.org · 717-356-5395
    • C.Anwar Chahal, MD,PhD · Principal investigator
  • Medical University of South Carolina (In Our DNA SC)
    Charleston, South Carolina 29425, United States
    Recruiting
    • Samantha Norman, MPH · Contactinourdnasc@musc.edu · 843-876-0582
    • Daniel Judge, MD · Principal investigator
  • Sanford Health (Imagine You)
    Sioux Falls, South Dakota 57105, United States
    Recruiting
  • Memorial Hermann Health System (genoME)
    Houston, Texas 77030, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — As a population health research network, the primary purpose of HRN is to help researchers and clinicians better understand how genetic information may be used to improve the health of individuals and communities. It is possible that participants may receive actionable health information as a result of analysis of their DNA information. This means that the participant's genetic results may be used by their healthcare providers to inform medical decisions. It is also possible that novel discoveries may be generated from the research that could positively impact a participant's healthcare in the future.

Supporting information: Informed consent form, Clinical study report

Time frame: Data will be available for the duration of the study.

Access criteria: An application to the Helix Research Network or a Member Site for Member Site level data.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Sep 2031, 120 months after the start.

Of 82 observational studies under Genetic Predisposition to Disease, half reached primary completion within 96 months of starting (the median), counting those still running; a quarter within 52. This study's planned 120 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2023
First posted
Sep 28, 2023
StartActual
Sep 13, 2021
Primary completionEst.
Sep 13, 2031
CompletionEst.
Sep 13, 2036
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
2000000→10000000
Nov 12, 2026
Interventions
Changed Exome sequencing→Exome+ sequencing and multi-omics
Nov 12, 2026
Sponsor
Collaborators added: TriHealth Inc.·LCMC Health
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Enrollment 2000000→10000000
    Interventions Changed Exome sequencing→Exome+ sequencing and multi-omics
    Sponsor Collaborators added: TriHealth Inc.·LCMC Health
    + 3 other changes: verification date, description and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06057181
Lead sponsor
Helix, Inc
Collaborators
Medical University of South Carolina, HealthPartners Institute, Memorial Hermann Health System, WellSpan Health, St. Luke's Hospital and Health Network, Pennsylvania, Sanford Health, Renown Health, WakeMed Health and Hospitals, University of Nebraska, Ohio State University, Cone Health, Parkview Health, Rochester Regional Health, University Health Network, Toronto, TriHealth Inc., LCMC Health
Responsible party
Sponsor
First posted
Sep 28, 2023
Start date
Sep 13, 2021
Primary completion
Sep 13, 2031 (estimated)
Completion
Sep 13, 2036 (estimated)
Last update
Nov 12, 2026

Study contacts

Layla Anderson
Contact
researchadmin@helix.com
206-295-8866
William Lee, PhD
principal investigator · Helix, Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion